鞘内注射曲妥珠单抗治疗乳腺癌合并脑膜转移患者。
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis.
机构信息
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Hospital Seoul, Seoul, Korea.
Division of Hematology-Oncology, Department of Internal Medicine, Soonchunhyang University Hospital Cheonan, Cheonan, Korea.
出版信息
Cancer Res Treat. 2016 Apr;48(2):843-7. doi: 10.4143/crt.2014.234. Epub 2015 Mar 2.
Leptomeningeal carcinomatosis is a fatal manifestation of metastatic breast cancer. Investigation of intrathecal (IT) trastuzumab for leptomeningeal carcinomatosis is currently underway; however, there has been no consensus. We report on two cases of human epidermal growth factor receptor 2 positive (HER2+) breast cancer following IT trastuzumab for leptomeningeal carcinomatosis. The first patient was treated with weekly IT 15 mg methotrexate plus IT 50 mg trastuzumab for 7 months, followed by IT trastuzumab (50 mg > 25 mg) for 18 months. The other patient received IT trastuzumab with systemic chemotherapy (trastuzumab and/or paclitaxel) for 13 months. Good control of leptomeningeal disease was achieved with IT trastuzumab in both patients, with survival durations of 20 and 29 months, respectively. We suggest that IT trastuzumab is a promising treatment for patients with HER2+ breast cancer and leptomeningeal carcinomatosis.
脑膜转移癌是转移性乳腺癌的一种致命表现。目前正在研究鞘内（IT）曲妥珠单抗治疗脑膜转移癌，但尚未达成共识。我们报告了两例人表皮生长因子受体 2 阳性（HER2+）乳腺癌患者在接受 IT 曲妥珠单抗治疗脑膜转移癌后的情况。第一例患者接受每周 IT 15 mg 甲氨蝶呤加 IT 50 mg 曲妥珠单抗治疗 7 个月，随后接受 IT 曲妥珠单抗（50 mg > 25 mg）治疗 18 个月。另一位患者接受 IT 曲妥珠单抗联合全身化疗（曲妥珠单抗和/或紫杉醇）治疗 13 个月。这两名患者均通过 IT 曲妥珠单抗实现了脑膜疾病的良好控制，生存时间分别为 20 个月和 29 个月。我们认为，IT 曲妥珠单抗是治疗 HER2+乳腺癌和脑膜转移癌患者的一种有前途的治疗方法。
Zotero 插件